Pet Cancer Therapeutics Market Key Futuristic Trends And Competitive Landscape 2018-2026


Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer. The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth. For instance, the scientists at University of Veterinary Medicine are currently exploring the molecular basis of cancer progression in canine cell lines, stating that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.

Market Dynamics:

The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2017, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.

Detailed Segmentation:

Global Pet Cancer Therapeutics Market, By Therapy Type:
Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

Global Pet Cancer Therapeutics Market, By Pet Type:
Cat
Dog
Horse

Global Pet Cancer Therapeutics Market, By Mode of Administration:
Oral
Intravenous
Topical

Global Pet Cancer Therapeutics Market, By Application:
Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

Global Pet Cancer Therapeutics Market, By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1284

Global Key Players:

Key companies covered as a part of this study include Aratana Therapeutics, Inc., AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Rhizen Pharmaceuticals SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, and Zoetis

Increasing Incidence And Remission Rates Of Pet Cancers To Accelerate The Market Growth:

Increasing prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the pet cancer therapeutics market growth during the forecast period. According to the study by Fetch a Cure, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer. According to the study published by Animal Cancer Foundation, 2017, approximately around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing number of relapsed cancer rates and the availability of relapsed/ refractory therapeutics integrated with veterinarian recommendation is expected to additionally generate the revenue for the market players.

According to the study by petMD, LLC, 2015, about 95% of dogs treated for lymphoma with chemotherapy protocols and conventional treatments are expected to experience disease relapse or remission. The duration of remission is less than 15 months in 50% of dog species. In 2017, a novel chemotherapy drug named Tanovea-CA1 (rabacfosadine for injection), manufactured by VedDC, Inc. was conditionally approved by the FDA as a first line treatment for dogs to treat relapsed/refractory lymphoma and canine lymphoma. The conditional approval of drug allows manufacturer to legally sell Tanovea-CA1, before proving it meets the substantial evidence standard of effectiveness for full approval.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments

Post a Comment

Popular posts from this blog

Why the Cold Pain Therapy is a Growing Payer Opportunity?

Image
Cold pain therapy is a therapeutic application of cold, used in the treatment of acute soft tissue injuries and to reduce the pain in post-operative condition in orthopedic surgeries, treatment of benign and malignant lesions, and in pain management. Cryotherapy can be applied topically (on the skin surface), surgically or percutaneously. This can also be used to treat various skin conditions such as oral mucositis and tumors in the liver, kidney, bones, breasts and lungs, skin tumors, skin tags, pre-cancerous skin moles, and injuries. Cryosurgery procedure involves use of extreme cold, produced with help of liquid nitrogen (or argon gas) to destroy abnormal tissues. According to the National Cancer Institute (NCI), cryosurgery is used for treatment of several types of cancers and some non-cancerous conditions. It is reported to be effective for treatment in early stage skin cancer, retinoblastoma, actinic keratosis, and cervical intraepithelial neoplasia. Accord...
Read more

Ursodeoxycholic Acid Market Shows Boosted Growth Rate 2018-2026 Estimated by Global Top Players

Image
Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent the progression of cystic fibrosis-related liver disorder. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover it can improve long-term survival in patients with primary biliary cirrhosis. Significant improvement in liver health can be achieved during UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases. The global ursodeoxycholic acid market size was valued at US$ 346.2 million in 2017, and is expected to witn...
Read more

Booms and Busts in Anatomic Pathology Market; Dynamics Trends Over The Time Discussed 2018-2026

Image
Anatomic pathology involves direct visualization of human tissue as gross examination as well as under a microscope for proper diagnosis of the disease or a pathological condition. Subtypes of anatomic pathology include surgical pathology, oral and maxillofacial pathology, cytopathology, molecular pathology, and forensic pathology. Procedures performed in anatomic pathology include gross examination, histopathology, immunohistochemistry, in situ hybridization, cryopathology, tissue cytogenetics, and others. Standard approach in anatomical pathology is microscopic examination of tissue samples with the help of one or more stains. Manufacturers have developed stains to identify and classify microorganisms in biopsy of tissue samples or excisional specimens. Various gram stains and acid-fast stains have applications in detection of bacteria and mycobacteria in tissue samples. Commercially available products include tissue processing systems, microtomes, cryostats, ...
Read more